Suchen
LENZ Therapeutics Inc
LENZZur Watchlist hinzufügen
5.890USD
+0.100+1.73%
Handelsschluss 07/02, 13:00（ET）Kurse um 15 Minuten verzögert
184.68MMarktkapitalisierung
VerlustKGV TTM
mehr Informationen über LENZ Therapeutics Inc Unternehmen
LENZ Therapeutics, Inc. is a pre-commercial stage biopharmaceutical company. The Company is focused on the development and commercialization of aceclidine-based eye drop to improve near vision in patients with presbyopia. The Company’s lead product candidate LNZ100 is a preservative-free, single-use, once-daily eye drop containing aceclidine. LNZ100 was evaluated in the registration-enabling Phase III CLARITY study as a potential therapy for the treatment of presbyopia, a condition impacting over 1.8 billion people globally and 128 million people in the United States. Its other product LNZ101, is a preservative-free eye drop containing aceclidine and brimonidine.
LENZ Therapeutics Inc Informationen
BörsenkürzelLENZ
Name des UnternehmensLENZ Therapeutics Inc
IPO-datumJun 25, 2021
CEOSchimmelpennink (Evert)
Anzahl der mitarbeiter42
WertpapierartOrdinary Share
GeschäftsjahresendeJun 25
Addresse- -
Stadt- -
BörseNASDAQ OMX - NASDAQ BASIC
Land- -
Postleitzahl- -
Telefon- -
Website- -
BörsenkürzelLENZ
IPO-datumJun 25, 2021
CEOSchimmelpennink (Evert)
Führungskräfte von LENZ Therapeutics Inc
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Dr. Frederic (Fred) Guerard, Pharm.D.
Dr. Frederic (Fred) Guerard, Pharm.D.
Independent Director
Independent Director
--
--
Jeff W. George
Jeff W. George
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Shelley B. Thunen
Ms. Shelley B. Thunen
Independent Director
Independent Director
--
--
Dr. Zachary (Zach) Scheiner, Ph.D.
Dr. Zachary (Zach) Scheiner, Ph.D.
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Aktienbesitz
Veränderung
Mr. James Mccollum
Mr. James Mccollum
Independent Director
Independent Director
631.10K
--
Mr. Marc Odrich
Mr. Marc Odrich
Chief Medical Officer
Chief Medical Officer
100.20K
+0.60%
Dr. Daniel R. (Dan) Chevallard
Dr. Daniel R. (Dan) Chevallard
Chief Financial Officer
Chief Financial Officer
12.89K
+58.20%
Mr. Shawn Olsson
Mr. Shawn Olsson
Chief Commercial Officer
Chief Commercial Officer
4.73K
--
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Ms. Kimberlee Cobleigh (Kim) Drapkin, CPA
Independent Director
Independent Director
--
--
Mr. Evert (Eef) Schimmelpennink
Mr. Evert (Eef) Schimmelpennink
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
--
--
Häufig gestellte Fragen
Wer sind die fünf größten Anteilseigner von LENZ Therapeutics Inc?
Die fünf größten Anteilseigner von LENZ Therapeutics Inc sind: Mr. James Mccollum
Wie viele Institutionen halten Anteile an LENZ Therapeutics Inc (LENZ)?
Mit Stand vom 2026Q1 halten 347 Institutionen Anteile an LENZ Therapeutics Inc, mit einem Gesamtmarktwert von etwa 36.30M, was 115.82% der Gesamtanteile entspricht. Im Vergleich zum 2025Q4 ist der institutionelle Aktienbesitz um 853081.00 gestiegen.